Posted on

Wuhan Announces Strategic Reorganization for Its Operational Advancement in the Medical Marijuana and Psilocybin Mushroom Therapy Markets

BARCELONA, Spain, Aug. 07, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Wuhan General Group, Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), is pleased to announce a strategic reorganization that will better position the company to capitalize on the rapidly changing Medical Marijuana and Psilocybin Mushroom industries, while more closely aligning the business with the company’s three primary growth strategies: optimizing the value of the core; increasing health and well-being product lines, and accelerating distribution of new business models.

“Throughout his tenure as CEO, Mr. Kamaneh was instrumental in leading Wuhan in surpassing many milestones, and he has provided sound financial leadership to the Company,” said Jeffrey Robinson, newly appointed CEO. Mr. Kamaneh’s transition as Chief Financial Officer within the company only strengthens managements with his more than fifteen years of experience in finance and various manufacturing industries. Ramy brings a rare combination of expertise leading both public companies and private companies through significant stages of growth. At Wuhan, he will support the company’s next level of expansion by aligning corporate finance with all aspects of the business, from engineering and manufacturing to logistics and operations.

Mr. Robinson further comments: “The transformative joint-venture partnership between Wuhan and Biodelta served as a catalyst for us to re-examine how to best organize the company for increased emphasis on execution and profitable growth. This strategic reorganization focusing on each of our own core strengths, the integration of Wuhan and Biodelta, and long-term growth provide the right structure for us to optimize the value of our businesses today while creating future-oriented opportunities.”

“Mr. Robinson’s appointment and this transition are essential milestones in a succession plan that the board of directors has been working on for the past months,” says Ramy Kamaneh. “Mr. Robinson’s people-focused leadership style, industry expertise, and market understanding will build on the success of the Company. Mr. Robinson is focused on the future and guiding Wuhan in achieving its long-term strategic goals.”

Additionally, Mr. Luka Marjanovic is joining the Wuhan team as Head of Product Development for the MJ MedTech division In South Africa. This new appointment solidifies Wuhan’s core business operations.  Mr. Marjanovic is responsible for the development, implementation, enhancement and support of the Dr. AnnaRx™ and Medspresso™ products, and delivery channels. This includes conceptual stages through research, development, marketing, training, performance tracking and the entire product life cycle in support of Wuhan’s strategic goals and objectives.

Mr. Marjanovic is taking an integrative approach to build solutions and drive product development. “I’m excited to work with the team and to be given the opportunity to apply strategic practices that I’ve gained through my prior experience as we continue to improve our products, processes, and scaling of our operations. The speed, frequency, and timeline of product releases for the Dr. AnnaRx™ line are very impressive,” says Mr. Marjanovic. “We plan to have 30 products in the pipeline by year-end.”

About Luka Marjanovic, BSc., MSc. 

Mr. Marjanovic holds a Bachelor’s in International Business from Denmark and a Master’s in International Management from ESADE Business & Law School. During his undergraduate studies, he founded his own consulting firm, providing services to local businesses in various sectors; as well as working as a research assistant in the field of Big Data. Prior to his education, he served in the Danish Royal Army as Second Sergeant, leading and managing a group of men, under extreme pressures and conditions. Luka has spent significant time abroad, living and working in six different countries, and is now responsible for designing business models and go-to-market strategies for Dr. AnnaRx™ and Medspresso™ products.

About Wuhan General Group, Inc.

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for new Psilocybin therapies that will help patients who suffer from mental illness, Alzheimer and Parkinson disease. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board under the trading symbol “WUHN”.

For further information:
Publicly traded company (OTC Pink: WUHN)
Website: www.wuhn.org
Public Relations E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the 

meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Primary Logo

Posted on

British Columbia PharmaCare Lists AbbVie’s Hepatitis C Treatment MAVIRET™ on its Formulary

  • British Columbia PharmaCare lists MAVIRET on its formulary effective March 21, 2019
  • MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment*1
  • MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease

 

MONTREAL, QC, March 22, 2019 – AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company, announced that MAVIRET™ (glecaprevir/pibrentasvir tablets) is now reimbursed in British Columbia. MAVIRET is a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6).2 It is the only 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment.*

 

In British Columbia, MAVIRET is reimbursed for the treatment of treatment-naïve or treatment- experienced adult patients with chronic hepatitis C including all genotypes 1-6. The listing became effective on March 21, 2019.3

 

“Hepatitis C represents a crisis in Canada and around the world. But it doesn’t have to be the case for much longer. We now have the ability to effectively screen, diagnose, treat and cure people living with this devastating disease,” explains Dr. Brian Conway, Infectious Diseases Specialist and medical director of the Vancouver Infectious Disease Centre. “When treatment is initiated earlier, with options such as MAVIRET, we have the potential to reduce transmission rates, the risk of death from associated conditions such as liver cancer and the long-term management costs of this disease. MAVIRET is an

important tool to help us achieve the World Health Organization objective of eliminating HCV as a public health concern in Canada by 2030.”

 

Approximately 300,000 Canadians are infected with hepatitis C.4 British Columbia has the highest rate of hepatitis C in Canada. There are an estimated 80,000 people living with the virus in the province and about 2,500 new cases of hepatitis C are identified each year.5

 

“The vision of our organization is for British Columbia to be free from new hepatitis C cases, while offering the best possible care and support for those already living with this disease,” said Daryl Luster, President of the Pacific Hepatitis C Network (PHCN). “Today, I am optimistic that this is well within our reach because we already have the right treatments that offer high cures. By collaborating together, we will be able to move towards the elimination of the hepatitis C virus in British Columbia and Canada.”

 

The efficacy and safety of MAVIRET was evaluated in nine Phase 2-3 clinical trials, in over 2,300 patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection and with compensated liver disease (with or without cirrhosis).

 

About MAVIRET™

MAVIRET™ is indicated in Canada for the treatment of chronic hepatitis C virus (HCV) infection in adults across all major genotypes (GT1-6).6 MAVIRET is a pan-genotypic, once-daily, ribavirin-free treatment that combines glecaprevir (100 mg), an NS3/4A protease inhibitor, and pibrentasvir (40 mg), an NS5A inhibitor, dosed once-daily as three oral tablets.6

 

MAVIRET is an 8-week, pan-genotypic virologic cure** for use in patients without cirrhosis and who are new to treatment,*1 such patients comprising the majority of people living with HCV. MAVIRET is also approved as a treatment for patients with specific treatment challenges, including those with compensated cirrhosis across all major genotypes, and those who previously had limited treatment options, such as patients with severe chronic kidney disease (CKD), post-liver and -renal transplant recipients *** and those patients with genotype 3 infection.6 It is the only pan-genotypic treatment approved for use in patients across all stages of CKD.6

 

Glecaprevir (GLE) was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals (NASDAQ: ENTA) for HCV protease inhibitors and regimens that include protease inhibitors.

 

*Patients without cirrhosis and new to treatment with DAAs [either treatment-naive or not cured with previous IFN-based treatments ([peg]IFN +/- RBV or SOF/RBV +/- pegIFN)].

**Patients who achieve a sustained virologic response at 12 weeks post treatment (SVR12) are considered cured of hepatitis C.

***MAVIRET is recommended for 12 weeks in liver or kidney transplant recipients who are HCV GT-1 to 6 treatment-naïve (TN) or GT-1, -2, -4, -5, -6 PRS- treatment experienced. A 16-week treatment duration should be considered in transplant patients who are GT-1 NS5A inhibitorexperienced (NS3/4A inhibitor-naïve) or GT-3 PRS- treatment experienced.

 

 

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 

###

 

Media:

Muriel Haraoui AbbVie Canada (514) 717-3764

muriel.haraoui@abbvie.com

 

1 Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016. January 2017.

2 CADTH Canadian Drug Expert Committee Recommendation – Final: https://www.cadth.ca/sites/default/files/cdr/complete/SR0523_Maviret_complete-Jan-25-18.pdf. Accessed March 2019. 3 British Columbia Pharmacare. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-

resources/pharmacare/prescribers/limited-coverage-drug-program/limited-coverage-drugs-glecaprevir-pibrentasvir. Accessed March 2019.

4 The Canadian Liver Foundation. https://www.liver.ca/how-you-help/advocate/. Accessed March 2019. 5 British Columbia Centre for Excellence in HIV/AIDS. Hepatitis C (HCV) Fact sheet. http://www.cfenet.ubc.ca/sites/default/files/uploads/HCV%20Fact%20Sheet.pdf. Accessed March 2019.

6 MAVIRET (glecaprevir/pibrentasvir tablets) Product Monograph. Date of Preparation: August 16, 2017. Date of Revision: November 28, 2018. http://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/MAVIRET_PM_EN.pdf. Accessed March 2019.

Posted on

BETTER PLANT’S HAND SANITIZER GEL APPROVED FOR LISTING ON AMAZON.COM

Vancouver, B.C. – October 6, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that Amazon.com has approved the listing for its hand sanitizer gel, which is manufactured by its subsidiary, Urban Juve. The hand sanitizer gel is listed with the FDA (NDC 75385-0010-1) and has received Natural Health Product Number 80098154 from Health Canada. Urban Juve’s Ultra Hydrating Hand Sanitizer Spray received Health Canada approval on March 27, 2020. The Hand Sanitizer Gel will be live on Amazon.com later this month. Both the Hand Sanitizer Gel and Spray are available for purchase on Amazon.ca and urbanjuve.com.

“The popularity of Amazon is undeniable”, says Gabe Villablanca, Better Plant’s Director of eCommerce. “During these times, it is becoming more and more simple and stress-free to shop online, so we want to expand that accessibility across the top platforms.” Earlier this year, Urban Juve’s full line went live on Amazon.ca, offering free shipping on orders over $35. Due to high demand, Urban Juve ensured the Hand Sanitizer Gel was the first product to be pushed through the approval process for Amazon.com. The Company plans to continue to use data to guide where they will make products available online for the convenience of consumers.

Based on a survey of more than 2,000 U.S.  customers, 89 percent of buyers agree that they’re more likely to buy products from Amazon than other eCommerce sites (Feedvisor, 2019).

 

About Better Plant Sciences Inc. 

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has over 200 proprietary wellness formulas at various stages of commercialization.  It operates websites and sells through eCommerce, Amazon and through a retail store network over 150 plant based products for body, baby and home under the brands JUSU, Urban Juve and Wright & Well. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing functional mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for Health Canada approval to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Kevan Matheson, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.